Synopsis:Pharma stock fell after reporting a 39 percent YoY drop in Q1 profit to Rs 786 crore, as higher raw material costs, margin pressure, and weaker North America sales weighed on earnings.
The share of this company, which is in the business of manufacturing, developing, and marketing a wide range of branded and generic formulations and APIs, came under pressure after posting weak Q1 numbers
With a market capitalization of Rs 1,12,711 crore, Cipla Ltd’s share on Thursday made a day low of Rs 1,366.20 per share, down by 3.45 percent from its previous day’s close price of Rs 1,415.10 per share. The share of the company gave a negative return of 5.33 percent over the last year.
QoQ View:
Revenue grew by 8.84 percent to Rs 7,119 crore in Q1 FY27 from Rs 6,541 crore in Q4 FY26, and EBITDA grew by 24.82 percent to Rs 1,192 crore in Q1 FY27 from Rs 955 crore in Q4 FY26. Accompanied by a net profit growth of 44.75 percent to Rs 786 crore in Q1 FY27 from Rs 543 crore in Q4 FY26, resulting in an EPS growth of 42.21 percent to Rs 9.77 per share in Q1 FY27 from Rs 6.87 per share in Q4 FY26.
YoY View
The sales grew by 2 percent YoY to Rs 7,119 crore in Q1 FY27 from Rs 6,957 crore in Q1 FY26, while EBITDA declined by 33 percent to Rs 1,192 crore in Q1 FY27 from Rs 1,778 crore in Q1 FY26. Accompanied by a net profit decrease of 39 percent to Rs 786 crore in Q1 FY27 from Rs 1,292 crore in Q1 FY26, resulting in an EPS decrease of 39 percent to Rs 9.77 per share in Q1 FY27 from Rs 16.06 per share in Q1 FY26.
Q1 Business Performance
India Business: Cipla’s India business reported its highest-ever quarterly sales, with revenue growing 12 percent YoY. The branded prescription business outperformed the Indian Pharmaceutical Market (IPM), growing 15.4 percent, while the chronic product mix improved to 60.4 percent. The trade generics business also posted healthy growth, supported by stronger distribution and three new product launches.
International Business: In North America, the company reported quarterly revenue of USD 162 million, supported by the launch of products such as gVentolin, Nintedanib, and Dapagliflozin. The Africa business maintained its No. 2 position in the prescription market, while the Emerging Markets and Europe business generated over USD 100 million in quarterly revenue, growing 5 percent YoY in dollar terms.
R&D and Financial Position: Cipla increased its R&D spending by 12.3 percent YoY to Rs 486 crore, accounting for 6.8 percent of quarterly sales, driven by higher product filings and development activities. The company also maintained a strong balance sheet with a net cash position of Rs 9,494 crore, providing financial flexibility to support future growth initiatives.
What went wrong in Q1?
Higher Raw Material Costs
Raw material expenses increased 22.8 percent YoY to Rs 2,667 crore in Q1 FY27, driven by higher input costs. The increase in material prices put pressure on the company’s gross margins and weighed on overall profitability during the quarter.
Sharp Margin Contraction
EBITDA declined 33 percent YoY to Rs 1,192 crore in Q1 FY27, while the EBITDA margin narrowed to 16.7 percent in Q1 FY27 from 25.6 percent in Q1 FY26. Higher raw material and operating costs significantly impacted the company’s operating performance.
Weak North America Performance
Revenue from the North America business declined to USD 162 million in Q1 FY27 from USD 226 million in Q1 FY26. The fall was mainly due to lower contribution from high-margin products, which affected the overall performance of the international business.
Higher Operating Expenses
Total expenses rose 14.4 percent YoY to Rs 5,927 crore in Q1 FY27, mainly due to higher employee and other operating costs. At the same time, lower other income during the quarter further weighed on the company’s overall profitability.
About the Company
Cipla is a leading Indian multinational pharmaceutical company headquartered in Mumbai, renowned for manufacturing affordable generic drugs, respiratory medications, and active pharmaceutical ingredients (APIs). Founded in 1935, the company operates in over 80 markets worldwide and ranks as the third-largest drug producer in India
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
